Results 191 to 200 of about 125,674 (260)

Bcr‐Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling

International Journal of Cancer, 2014
Jing Yang, T. Ikezoe, C. Nishioka, K. Udaka, A. Yokoyama   +4 more
semanticscholar   +1 more source

The Emergence of a Novel Insertional Mutation in the BCR::ABL/p210 Oncogene in B-Cell Acute Lymphoblastic Leukemia (B-ALL) Correlates with the Development of Resistance to Several Tyrosine Kinase Inhibitors. [PDF]

Acta Naturae
Bogdanov KV, Kudryavtseva ES, Lobacheva YN, Merzlikina OV, Mirolyubova YV, Vlasik RA, Badaev RS, Lomaia EG.   +7 more
europepmc   +1 more source

Mebendazole effectively overcomes imatinib resistance by dual-targeting BCR/ABL oncoprotein and β-tubulin in chronic myeloid leukemia cells. [PDF]

Korean J Physiol Pharmacol
Yang L, Du Z, Peng Y, Zhang W, Feng W, Yuan Y.   +5 more
europepmc   +1 more source

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.

Blood, 2013
S. Soverini, C. Benedittis, K. Polakova, A. Broučková, D. Horner, M. Iacono, F. Castagnetti, G. Gugliotta, F. Palandri, C. Papayannidis, I. Iacobucci, C. Venturi, M. Bochicchio, H. Klamová, F. Cattina, D. Russo, P. Bresciani, G. Binotto, B. Giannini, A. Kohlmann, T. Haferlach, A. Roller, G. Rosti, M. Cavo, M. Baccarani, G. Martinelli   +25 more
semanticscholar   +1 more source

Rational Approach to New Chemical Entities with Antiproliferative Activity on Ab1 Tyrosine Kinase Encoded by the BCR-ABL Gene: An Hierarchical Biochemoinformatics Analysis. [PDF]

Pharmaceuticals (Basel)
Sanches VHDS, Lobato CC, Silva LB, Dos Santos IVF, Barros ES, Maciel AA, Ferreira EFB, da Costa KS, Espejo-Román JM, Rosa JMC, Kimani NM, Santos CBR.   +11 more
europepmc   +1 more source

The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.

Blood, 1996
J. Melo
semanticscholar   +1 more source

Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN. [PDF]

J Nanobiotechnology
Sun Y, Wang Y, Liu C, Huang Y, Long Q, Ju C, Zhang C, Chen Y.   +7 more
europepmc   +1 more source

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

Blood, 2003
S. Branford, Z. Rudzki, Sonya Walsh, I. Parkinson, A. Grigg, J. Szer, K. Taylor, R. Herrmann, J. Seymour, C. Arthur, D. Joske, K. Lynch, T. Hughes   +12 more
semanticscholar   +1 more source

Significance of Somatic Mutation Profiling in CML Beyond BCR-ABL: A Retrospective Study of the Indian Population. [PDF]

Indian J Hematol Blood Transfus
Chaudhary P, Chaudhary S, Patel F, Patel S, Patel D, Patel L, Trivedi N, Vaishnani T, Jajodia E, Ahmad F, Arora N.   +10 more
europepmc   +1 more source

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Blood, 2007
H. Kantarjian, F. Giles, N. Gattermann, K. Bhalla, G. Alimena, F. Palandri, G. Ossenkoppele, F. Nicolini, S. O’Brien, M. Litzow, R. Bhatia, F. Cervantes, A. Haque, Y. Shou, D. Resta, A. Weitzman, A. Hochhaus, P. le Coutre   +17 more
semanticscholar   +1 more source